What TrialJectory does

TrialJectory, doing business as Leal Health, operates an AI-powered decision support platform that helps cancer patients identify personalized treatment options and clinical trials. The patient experience is fully self-serve: users select their cancer type, complete a 2-minute questionnaire, and receive an instantly generated, shareable list of treatments matched to their specific diagnosis. The matching engine is supplemented by a dedicated human support team of PhDs, MDs, Nurses, and Social Workers who spend approximately four hours per patient on education and advocacy. To date the platform reports over 3,125,000 treatment matches completed.

The product surface expanded in 2023 with an oncologist-facing module that delivers personalized clinical trial matches to providers, positioning the company for B2B monetization alongside the free patient-facing tool. Distribution is direct-to-consumer via leal.health and amplified through 22+ partnerships with patient advocacy organizations including the American Cancer Society, Colorectal Cancer Alliance, Tempus, MPN Research Foundation, NCCN, Sharsheret, Breast Cancer Alliance, and The Jackson Laboratory's Maine Cancer Genomics Initiative. The decision support service holds FDA approval, and the company has earned external recognition including Time Magazine Best Inventions (2020), Fast Company World Changing Ideas (2021), and Business Insider Most Promising Healthcare Startups (2023).

Revenue mechanics are not publicly disclosed. The patient-facing service is free, and the input material indicates no pricing model, contract structure, paying customer logos, funding rounds, headcount, ownership, or management team information. This represents a significant analytical gap. Available evidence suggests B2B monetization through pharma, payer, or health system relationships is the most likely revenue vector, but no commercial terms are confirmed.

Name

TrialJectory

Website

https://trialjectory.com

Company type

Private

Operating status

Operating

Short description

Leal Health (formerly TrialJectory) operates an AI-powered decision support platform that matches cancer patients with personalized treatment options and clinical trials. The free, direct-to-consumer service reports over 3.1 million treatment matches and integrates with 22+ patient advocacy organizations and clinical partners.

Ownership category

akta.pro rank

Product category

Cancer Treatment Decision Support

NAICS

Management Consulting Services (54161)

SIC

Services-Health Services (8000), Services-Prepackaged Software (7372)

akta.pro primary industry

Order Sets, Care Plans & Clinical Pathways (CPOE-integrated) (HLACAGAC)

Keywords

• Clinical trial matching
• Cancer treatment platform
• Patient decision support
• Oncology treatment matching
• AI healthcare platform

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Markets served

GTM type

B2C

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

1. Patient-facing service: The platform is offered free to patients. Revenue model is not explicitly disclosed in available source material. The company positions itself as democratizing access to cancer treatment without pharma bias, suggesting potential partnerships with healthcare systems, pharmaceutical companies, or payers rather than direct patient charges.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

TrialJectory (doing business as Leal Health) operates an AI-powered cancer treatment decision support platform that enables patients to receive personalized treatment recommendations. Patients select their cancer type, complete a 2-minute questionnaire, and instantly receive a shareable personalized list of cutting-edge treatments and clinical trials matched to their exact diagnosis. The platform is FDA-approved, provided free of charge to patients, and is supported by a dedicated clinical team of PhDs, MDs, Nurses, and Social Workers averaging 4 hours of support per patient.

Product overview

Leal Health operates as a single unified AI-powered platform focused on democratizing access to advanced cancer treatment. The core offering is an AI-driven decision support platform that processes patient diagnosis information through a questionnaire-based intake system and instantly generates personalized, shareable lists of cutting-edge cancer treatments matched to each patient's exact condition. The platform combines AI-powered instant matching technology with dedicated human support from a team of PhDs, MDs, Nurses, and Social Workers who provide educational support to patients.

Differentiator

Problem solved

Functional benefit

Products and services

• AI-Powered Cancer Treatment Decision Support Platform

Quantifiable outcome

• Over 3,125,000 treatment matches made for patients
• +2 more outcomes

Named customers4 records

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature2 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• American Cancer SocietycoreGTM or Marketing PartnerMajor cancer advocacy organization partnership to direct patients to the platform for unbiased treatment matching
• TempuscoreTechnology or IntegrationLife sciences clinical trial solutions partnership for matching patients with clinical trials
• Colorectal Cancer AlliancecoreGTM or Marketing PartnerPatient support organization partnership providing clinical trial finder capabilities for colorectal cancer patients
• MPN Research FoundationminorGTM or Marketing PartnerMPN clinical trials partnership directing myeloproliferative neoplasm patients to the platform
• SummusminorStrategic or Co-development PartnerAnnounced collaboration to provide cancer patients with access to expert medical perspectives and treatment matching
• SharsheretminorGTM or Marketing PartnerBreast cancer support organization directing patients to treatment matching services
• Breast Cancer AllianceminorGTM or Marketing PartnerBreast cancer advocacy organization partnership for patient referrals
• NCCN (National Comprehensive Cancer Network)minorGTM or Marketing PartnerPatient resources partnership providing support group referrals to patients

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Syapse: Syapse focuses on real-world evidence in oncology, partnering with health systems and pharma. While more focused on provider-side data aggregation than patient-facing matching, they compete for similar oncology AI/data budgets from pharma customers.
• Flatiron Health: Flatiron Health (Roche subsidiary) provides oncology-specific EHR, real-world evidence, and clinical trial solutions. They are a broader incumbent in oncology data and trial matching with established pharma relationships that pose competitive and partnership opportunities for Leal.
• IQVIA: IQVIA is a global leader in clinical research services, real-world evidence, and healthcare data analytics. While operating at vastly larger scale across all therapeutic areas, they directly compete for pharma clinical trial recruitment budgets and could acquire or replicate Leal's capabilities.

Direct peers

• Tempus: Tempus is a technology company focused on precision medicine through AI and data analytics. While Tempus serves both clinical trial matching and broader genomic profiling, they are Leal's explicit integration partner for clinical trial solutions, making them the closest comparable in AI-driven oncology decision support infrastructure.
• Deep 6 AI: Deep 6 AI uses AI and natural language processing to match patients to clinical trials, with a focus on accelerating patient recruitment for sponsors and health systems. They directly compete with Leal for pharma clinical trial matching budgets.
• Outcomes4Me: Outcomes4Me is an AI-driven platform that empowers cancer patients with personalized treatment options and clinical trial matching. They share Leal's direct-to-consumer oncology patient focus and similar AI decision support value proposition.
• Mendel: Mendel applies AI to clinical trial recruitment and real-world evidence, with an enterprise focus on pharma and providers. While more enterprise-oriented than Leal, they directly compete in the AI-powered clinical trial matching space and target similar pharma customers.
• Cure Forward: Cure Forward operates a patient-facing platform for clinical trial matching and treatment options, with a similar focus on oncology patient empowerment. They compete directly for the same patient audience and pharma recruitment dollars.
• Antidote Me: Antidote is a digital health company that uses structured data and AI to match patients to clinical trials, with a strong oncology focus. They share the patient-facing clinical trial matching model and target the same pharma sponsorship revenue streams.
• Massive Bio: Massive Bio uses AI to match cancer patients with clinical trials, operating with a similar patient-facing B2C/B2B model. They directly compete with Leal in oncology clinical trial matching and treatment decision support.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TrialJectory